Bemdaneprocel is under clinical development by BlueRock Therapeutics and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Bemdaneprocel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DA-01 is under development for the treatment of Parkinson's disease. The therapeutic candidate comprises of human pluripotent embryonic stem cells derived dopamine neurons that can replace dopamine secreting cells. It is administered through parenteral route.
BlueRock Therapeutics overview
BlueRock Therapeutics, a subsidiary of Bayer AG, is an engineered cell therapy company that develops regenerative medicines to treat neurology, cardiology and immunology diseases. It is investigating its lead program, an authentic cellular therapy candidate to treat Parkinson’s disease. The company utilizes cell+gene technology platform to develop medicines against tauopathies, lysosomal storage disorders, acute injuries, chronic neuroinflammation, multiple sclerosis, hirschsprung’s disease, diabetic gastroparesis, autoimmune disorders, fibrosis, and Crohn’s disease. The company has operations in Canada and the US. BlueRock Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Bemdaneprocel’s drug-specific PTSR and LoA scores, buy the report here.